identified in chicken from retail and slaughter by CIPARS and has been isolated from other animal species such as pigs, turkeys, cattle, and horses, but at lower prevalences [6, 7] .
Antimicrobial resistance (AMR) may increase the burden of illness of Salmonella by increasing the number of infections, enhancing severity and duration of illness and causing antimicrobial treatment failure [8] .
Estimates from the United States suggest that an additional 29 379 Salmonella infections occur annually due to AMR, leading to 342 additional hospitalizations and 12 deaths [8] . Although antimicrobial therapy is not indicated for treatment of uncomplicated gastrointestinal illness [1] , Danish and US studies found that 36% and 40%, respectively, of patients with salmonellosis received antimicrobial treatment [9, 10] .
In assessing the risk to human health from antimicrobial use (AMU) in agriculture, the Institute of Medicine (IOM) in 1989 defined the etiologic fraction for prior AMU and resistant Salmonella infection (EF AMU-R ) as the proportion of human cases that would not occur "but for the resistance of the infecting bacterial strain to the antimicrobial(s) being administered" to the patient prior to infection [11] . The IOM used this to calculate the number of excess cases (ECs) from prior antimicrobial consumption. Human AMU can be a risk factor for salmonellosis by means of 2 possible effects. The competitive effect results from the reduction of competing commensal gastrointestinal flora, whereas the selective effect refers to increasing vulnerability of infection with Salmonella strains resistant to the antimicrobial being taken prior to infection for an unrelated reason [8] . Studies consider the combination of these effects by incorporating healthy controls as comparisons.
In humans, the third-generation cephalosporin ceftriaxone is used for the treatment of invasive salmonellosis and salmonellosis in children and pregnant women. Ceftriaxone resistance confers resistance to another third-generation cephalosporin, ceftiofur. In Canada, ceftiofur is approved for use in cattle, swine, horses, sheep, dogs, and cats [12] ; however, it is not approved for use in chickens or people. Its extralabel use in ovo for the control of Escherichia coli omphalitis in young chicks is legal in Canada. Currently, extralabel drug use is considered a tool for veterinarians within a valid veterinarian-client-patient relationship by Health Canada, although extralabel use of third-generation cephalosporins is not recommended [13] . A hatchery questionnaire conducted in Québec (2003 Québec ( -2004 found that ceftiofur was used in all eggs from 78% of the lots [14] . Québec hatcheries ceased using ceftiofur in 2005 in response to CIPARS results until late 2006 when they reinstituted rotational use. Within Québec, the prevalence of ceftiofur resistance in S. Heidelberg (from retail chicken and people) dropped significantly during the withdrawal period, but is rising again [6] . In 2010, Dutil et al [12] reported a significant temporal correlation between the prevalence of ceftiofurresistant S. Heidelberg from retail chicken and humans in Québec.
These temporal correlations raise questions about the direct burden of illness of S. Heidelberg. In lieu of Canadian studies that evaluate this direct burden, quantitative risk models can estimate case numbers by incorporating a stochastic process to account for uncertainty in the data [15, 16] . One such example was the US Food and Drug Administration (FDA) report, "Human health impact of fluoroquinolone resistant campylobacter attributed to the consumption of chicken" [17] .
The objective of this study was to estimate the annual number of human cases of S. Heidelberg in Québec and Ontario, the number of cases of ceftiofur-resistant S. Heidelberg attributable to eating chicken, the proportion of these cases attributable to human prior antimicrobial consumption (the EF AMU-R ), and the related number of ECs.
MATERIALS AND METHODS
A stochastic model was developed using the framework of the FDA's model for human infection with fluoroquinoloneresistant Campylobacter [17] . Separate models were run to estimate case numbers of S. Heidelberg for Québec and Ontario for each year from 2003 to 2011. Case incidences were calculated by standardizing these numbers using the provincial populations for each year as reported by Statistics Canada [18] .
Estimates from the stochastic models incorporated uncertainty around the input variables. The modeling approach included 4 sections ( Figure 1 ): (1) estimation of the annual reported, laboratory-confirmed S. Heidelberg cases for invasive infections and nonbloody and severe diarrhea (bloody or duration >7 days) using annual Canadian surveillance data (2003-2011); (2) estimation of the annual expected cases in the population using Canadian parameters for underascertainment (underreporting and underdiagnosis) [19] ; (3) estimation of the annual ceftiofur-resistant cases attributable to eating chicken meat using annual CIPARS surveillance data (2003-2011) and a static Canadian etiologic fraction for chicken (EF chicken ) [3] ; and (4) estimation of the annual ECs attributable to human prior antimicrobial consumption within the past month using the EF AMU-R , and those ECs that were attributable to eating chicken meat. The annual EF AMU-R was estimated using a static odds ratio for the combined effect (OR both ) of the competitive and selective effects of prior antimicrobial consumption and annual Canadian provincial data for antimicrobial prescriptions (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) to determine the annual prevalence of exposure -the proportion of people taking antimicrobials in the past month (P) in Québec and Ontario. The OR both was estimated using the outputs from a cumulative, random-effects meta-analysis of multiple published studies.
Model parameters, descriptions, and distributions are shown in Table 1 . Detailed descriptions of the data sources, model framework, distributions, assumptions, meta-analysis, and references are provided in the Supplementary Data. Key model assumptions included the following:
1. The annual proportions of human ceftiofur-resistant S. Heidelberg isolates reported by CIPARS were the same as those in the general population.
2. The estimates used to model the underascertainment of S. Heidelberg were the same as Canadian estimates used to model that for nontyphoidal Salmonella [19] , and these were constant over time.
3. The EF chicken for S. Heidelberg cases from eating all chicken meat was equivalent to that for eating chicken nuggets/strips as derived from Currie et al [3] , and this was constant over time.
4. The OR both for prior consumption of cephalosporins and infection with ceftiofur-resistant S. Heidelberg was the same as that for prior consumption of any antimicrobial and infection with antimicrobial resistant nontyphoidal Salmonella as derived from the meta-analysis.
5. The OR both and P to calculate EF AMU-R for ceftiofurresistant S. Heidelberg were based on consumption of any antimicrobial, the OR both was constant over time, and people were taking antimicrobials for reasons unrelated to gastrointestinal illness.
The model was constructed and simulated using @RISK (version 6.0.0, Palisade Corporation, Ithaca, New York) in Excel 2010 (Microsoft Office Professional Edition 2010, Microsoft Corporation, Redmond, Washington). It was run for 100 000 iterations, using Latin hypercube sampling with a Mersenne twister random number generator and a fixed initial seed. The advanced sensitivity analysis function in @RISK was used to identify the relative contributions of input distributions to the model outputs by generating tornado plots of conditional output means for percentiles of the input distributions [20] . Further sensitivity analysis used fixed values for input variables to specify their impact on ceftiofur-resistant cases from chicken and ECs from chicken. Values were fixed independently for inputs that had large contributions to the model outputs as Table 1 . 
The same calculations 
RESULTS
The estimated annual number of S. Heidelberg cases (mean per 100 000 population), after accounting for underascertainment, ranged from 29 to 82 in Québec and 30 to 73 in Ontario ( Using the meta-analysis estimate for the OR both (3.76 [standard error, 0.22]), the mean estimated OR both was 3.9 (95% CrI, 2.4-5.8). The reported provincial values for (P) ranged from 4.5%-5.1% and 5.6%-6.2% for Québec and Ontario, respectively. Using the OR both and P, the mean EF AMU-R for Québec over time ranged from 11.4% to 12.5% compared with 13.7% to 14.9% for Ontario. Annual provincial estimates of ECs are presented in Table 3 .
An example tornado plot of the conditional mean ECs from chicken in Québec for 2004 over percentiles of the input distributions from the advanced sensitivity analysis in @RISK is shown in Figure 3 . This plot ranks the inputs based on their largest impact on the magnitude of the change in mean ECs over the distribution of each input variable. For Québec and Ontario, the inputs with the largest impact on the conditional annual mean of ECs from chicken were (results not shown) the OR both ; the EF chicken ; the annual prevalence of ceftiofur resistance; the probability of stool submission; and the probability of seeking care for cases with nonbloody or severe diarrhea. Results from the sensitivity analysis for EF chicken and OR both are shown in Table 4 . As the fixed value for EF chicken increased, the incidence of ceftiofur-resistant cases from chicken increased. Increasing the OR both had the same impact on the ECs from chicken.
DISCUSSION
This model provides estimates of the number of human S. Heidelberg cases in Québec and Ontario after accounting for underascertainment and uncertainty. The estimates of ceftiofur-resistant S. Heidelberg cases attributable to eating chicken and those ECs attributable to human prior antimicrobial consumption and infection with a ceftiofur-resistant strain provide the basis for further work to determine excess costs to the healthcare system and other patient-related burden of illness metrics related to AMR. They can also be used to evaluate the effectiveness of future public health interventions to address AMR.
The number of human cases of ceftiofur-resistant S. Heidelberg attributable to eating chicken in Québec and Ontario changed over time relative to changing AMU practices in the Québec poultry industry [12, 14] . In Québec, the mean number of cases dropped from a high of 587 in 2004 to 53 in 2007. This drop in the number of cases alone would create beneficial public health impacts. The number of potentially preventable (excess) cases attributed to chicken consumption, prior antimicrobial consumption, and being infected with a resistant strain was estimated to be 71 in 2004 in Québec and dropped to 6 in 2007. Ontario had similar trends. The preventable cases attributed to prior antimicrobial consumption (from all sources) had a similar drop. This may be due to a decrease in P from 61% (2004) to 54% (2007), but could also be due in part to the decreasing trend of reported S. Heidelberg cases over this time period.
Previous analysis of CIPARS surveillance data demonstrated a significant temporal association between the annual prevalence of ceftiofur-resistant S. Heidelberg from retail chicken across Canada and the incidence of ceftiofur-resistant S. Heidelberg in people [12] . This model expands this work by providing an estimate of the potential number of cases attributable to chicken consumption and human prior antimicrobial consumption with attendant uncertainty. The drop in the estimated number Further understanding of these relationships requires detailed information on AMU in the poultry industry and for human cases, as well as source attribution studies.
This study provides a Canadian-specific EF AMU-R for ceftiofur-resistant S. Heidelberg based on Canadian data. The EF AMU-R for the combined effect ranged from 11% to 15% using the estimated OR both and Canadian provincial antimicrobial prescription data for P. The estimated OR both (3.9) was similar to the IOM's qualitative estimate for AMU and Salmonella (5 [range, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ) [11] and to Barza and Travers's estimate for nontyphoidal Salmonella (5.3 [95% confidence interval, 1.4-21.0]) [8] . Monthly prescription estimates ranged from 4.5% to 6.2% in both provinces. Barza and Travers used estimates between 6.6% and 15%, based on literature values [8] , compared to 0.2%-1.0% used by the IOM [11] . Published estimates for the EF AMU-R vary widely with inputs for the OR and P. One study reported an EF AMU-R of 16%-64% based on a review of studies specific to different sources and Salmonella serovars [21] compared with the IOM estimate of 2% (range, 0.5%-9%) [11] . However, these studies did not separate out the competitive, selective, or combined effects. The Barza and Travers estimate for the selective EF AMU-R (13%-26%) [8] is comparable to another study of multidrug-resistant S. enterica serovar Typhimurium that reported selective and combined EF AMU-R of 20% and 17%, respectively [22] .
The EF AMU-R suggests the number of cases that could be prevented by removing human antimicrobial exposure, or "preventable cases," assuming a causal relationship [11] . The data used to estimate the OR both for the EF AMU-R were based on a meta-analysis of studies relating antimicrobial consumption of any drug class to resistant, nontyphoidal Salmonella infection. They were not necessarily specific to ceftiofur-resistant S. Heidelberg, and, often, the type of antimicrobial used was not documented in the study. As a result, annual Canadian data for prescriptions for all antimicrobial classes were used to determine P, as opposed to specific cephalosporin use or other drug classes that may have genetically linked resistance mechanisms. At this time, there are no published studies that ascertain the direct causal link between prior cephalosporin consumption and clinical infection with ceftiofur-resistant S. Heidelberg.
Further research into Canadian temporal variations for the EF chicken and the OR both for prior antimicrobial consumption, including cephalosporin consumption specific to S. Heidelberg cases, would improve the estimated outputs from this model. A small number of studies were used to determine the OR both and not all of these were from Canada, as purely Canadian studies were not available. Both the EF chicken and OR both likely vary over time, but due to lack of temporal data, they were kept constant from year to year. This is comparable to the FDA model for ciprofloxacin-resistant Campylobacter that also considered a static EF chicken [17] . Also similar to the FDA model, this model does not account for cross-contamination between chicken and other foods. The EF chicken was based on one Canadian outbreak investigation for S. Heidelberg, with inputs specific for consumption of chicken nuggets and strips [3] . This was used as a proxy for all chicken consumption due to lack of other Canadian data. The fraction from egg consumption was not included as ceftiofur is not used in the Canadian layer industry (due to the lack of an approved product with a withdrawal time) and as the model results are related to changes in ceftiofur use by the broiler industry [23] . Appropriate measures for the burden of illness of antimicrobial resistant pathogens are important for evaluating public health impacts. This is particularly important when assessing potential risk reduction strategies for foodborne AMR, such as reducing or changing veterinary and agricultural AMU. This model provides the first Canadian estimates for annual numbers of human cases of ceftiofur-resistant S. Heidelberg and those attributable to chicken consumption. It provides the first Canadian estimate of the excess ceftiofur-resistant cases from chicken that are attributable to human prior antimicrobial consumption and being infected with a ceftiofur-resistant strain. Future work for ceftiofur-resistant S. Heidelberg could include incorporation of the impact of increased virulence and severity of infection [8] (eg, prolonged days of diarrhea, increased hospitalization rates, increased length of hospital stay, potential treatment failure, increased mortality, and increased risk of other chronic sequelae). Quantitative AMU information from the broiler chicken sector and human cases would improve the understanding of the relationship between changes in AMU in comparison to changes in resistance. Source attribution through genetic fingerprinting of S. Heidelberg isolates from hatchlings, retail chicken, and humans over time would create a clearer picture of the movement of resistance determinants between chickens and people. Abbreviations: EF chicken , etiologic fraction for chicken consumption; OR both , odds ratio for the combined effect of prior antimicrobial consumption within the past month.
